Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies.
作者信息
Ravandi F, Pigneux A, DeAngelo D J, Raffoux E, Delaunay J, Thomas X, Kadia T, Kantarjian H, Scheuenpflug J, Zhao C, Guo W, Smith B D
机构信息
Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Service des Maladies du Sang, Centre François Magendie, Hôpital du Haut-Lévèque, Pessac, France.
出版信息
Blood Cancer J. 2015 Dec 11;5(12):e375. doi: 10.1038/bcj.2015.103.
Abstract
摘要
相似文献
1
Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies.MEK1/2抑制剂匹马替尼用于晚期血液系统恶性肿瘤患者的临床、药代动力学和药效学数据。
Blood Cancer J. 2015 Dec 11;5(12):e375. doi: 10.1038/bcj.2015.103.
2
Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.选择性MEK1/2抑制剂匹美替尼的药理学
Eur J Drug Metab Pharmacokinet. 2018 Aug;43(4):373-382. doi: 10.1007/s13318-018-0466-x.
3
Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.甲状腺癌患者莫特塞尼布治疗后肿瘤退缩时间的群体药代动力学/药效学模型。
Cancer Chemother Pharmacol. 2010 Nov;66(6):1151-8. doi: 10.1007/s00280-010-1456-0. Epub 2010 Sep 25.
4
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.CT-011（一种与程序性死亡受体1相互作用的人源化抗体）在晚期血液系统恶性肿瘤患者中的I期安全性和药代动力学研究。
Clin Cancer Res. 2008 May 15;14(10):3044-51. doi: 10.1158/1078-0432.CCR-07-4079.
5
Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.匹马替尼，一种选择性口服MEK1/2抑制剂：癌症患者中的绝对生物利用度、质量平衡、消除途径及代谢物谱。
Br J Clin Pharmacol. 2016 Dec;82(6):1498-1508. doi: 10.1111/bcp.13078. Epub 2016 Sep 19.
6
Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors.在实体瘤患者中，MEK1/2抑制剂匹马替尼的代谢涉及与磷酸乙醇胺的新型缀合。
Drug Metab Dispos. 2017 Feb;45(2):174-182. doi: 10.1124/dmd.116.072934. Epub 2016 Dec 1.
7
Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.一项评估在研口服血管生成抑制剂 motesanib 在日本晚期实体瘤患者中的安全性、耐受性、药代动力学和初步疗效的 1 期研究。
Cancer Chemother Pharmacol. 2010 Oct;66(5):935-43. doi: 10.1007/s00280-010-1243-y. Epub 2010 Jan 28.
8
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.莫替沙尼用于进展期或有症状的晚期或转移性甲状腺髓样癌患者的安全性和有效性的II期研究。
J Clin Oncol. 2009 Aug 10;27(23):3794-801. doi: 10.1200/JCO.2008.18.7815. Epub 2009 Jun 29.
9
Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.口服环吡酮胺在晚期血液恶性肿瘤患者的 I 期研究中表现出生物活性。
Am J Hematol. 2014 Apr;89(4):363-8. doi: 10.1002/ajh.23640. Epub 2014 Mar 3.
10
Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.一名肝细胞癌患者出现的索拉非尼相关性银屑病样皮疹。
J Drugs Dermatol. 2014 Aug;13(8):899-900.
引用本文的文献
1
Pimasertib Versus Dacarbazine in Patients With Unresectable -Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover.皮马替尼与达卡巴嗪治疗不可切除的BRAF V600E突变皮肤黑色素瘤患者：一项II期交叉随机对照试验
Cancers (Basel). 2020 Jun 29;12(7):1727. doi: 10.3390/cancers12071727.
2
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.RAS 突变型急性髓系白血病中 MEK 抑制剂 Binimetinib（MEK162）的 II 期临床试验。
Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):142-148.e1. doi: 10.1016/j.clml.2018.12.009. Epub 2018 Dec 20.
3
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.一项评估 HDM2 拮抗剂 SAR405838 联合 MEK 抑制剂 pimasertib 治疗晚期实体瘤患者的 I 期临床研究。
Br J Cancer. 2019 Feb;120(3):286-293. doi: 10.1038/s41416-018-0355-8. Epub 2018 Dec 26.
4
Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.选择性MEK1/2抑制剂匹美替尼的药理学
Eur J Drug Metab Pharmacokinet. 2018 Aug;43(4):373-382. doi: 10.1007/s13318-018-0466-x.
5
Protein kinase inhibitors for acute leukemia.用于急性白血病的蛋白激酶抑制剂
Biomark Res. 2018 Feb 13;6:8. doi: 10.1186/s40364-018-0123-1. eCollection 2018.
本文引用的文献
1
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.急性髓系白血病的发生是由独特的体细胞突变所定义的。
Blood. 2015 Feb 26;125(9):1367-76. doi: 10.1182/blood-2014-11-610543. Epub 2014 Dec 30.
2
NRAS mutations in de novo acute leukemia: prevalence and clinical significance.初发急性白血病中的NRAS突变：发生率及临床意义
Indian J Biochem Biophys. 2014 Jun;51(3):207-10.
3
MEK and the inhibitors: from bench to bedside.MEK 抑制剂：从实验室到临床。
J Hematol Oncol. 2013 Apr 12;6:27. doi: 10.1186/1756-8722-6-27.
4
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.PI3K 和 MEK 抑制剂联合治疗：在选定肿瘤类型中评估证据。
Cancer Chemother Pharmacol. 2013 Jun;71(6):1395-409. doi: 10.1007/s00280-013-2121-1. Epub 2013 Feb 27.
5
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.联合 PI3K/mTOR 和 MEK 抑制在忠实的鼠类癌症模型中提供广泛的抗肿瘤活性。
Clin Cancer Res. 2012 Oct 1;18(19):5290-303. doi: 10.1158/1078-0432.CCR-12-0563. Epub 2012 Aug 7.
6
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.靶向治疗癌症中的 MAPK-RAS-RAF 信号通路。
Expert Opin Ther Targets. 2012 Jan;16(1):103-19. doi: 10.1517/14728222.2011.645805. Epub 2012 Jan 12.
7
A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.一种 MEK 抑制剂可消除 Kras 突变小鼠的骨髓增生性疾病。
Sci Transl Med. 2011 Mar 30;3(76):76ra27. doi: 10.1126/scitranslmed.3001069.
8
MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.MEK1/2 抑制剂 AS703026 和 AZD6244 可能是针对 EGFR 单克隆抗体治疗耐药的 KRAS 突变型结直肠癌的潜在治疗方法。
Cancer Res. 2011 Jan 15;71(2):445-53. doi: 10.1158/0008-5472.CAN-10-3058. Epub 2010 Nov 30.
9
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.新型选择性 MEK1/2 抑制剂 AS703026 阻断 MEK/ERK 信号级联，在体内外诱导多效性抗骨髓瘤活性。
Br J Haematol. 2010 May;149(4):537-49. doi: 10.1111/j.1365-2141.2010.08127.x. Epub 2010 Mar 12.
10
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia.复发和难治性原发性急性髓系白血病中 ERK 磷酸化和调控的单细胞定量测定
Leukemia. 2005 Sep;19(9):1543-9. doi: 10.1038/sj.leu.2403859.
Zotero 插件